Biotin Interference with Laboratory Tests: Troponin, Thyroid, and Diagnostic Accuracy Warnings

Dermatological Safety Alert: This page covers supplement interactions with skin medications and dermatologic treatments. If you take prescription retinoids, immunosuppressants, photosensitizing medications, or are undergoing dermatological procedures, do not start any supplement without discussing it with your dermatologist or healthcare provider. Some interactions can worsen skin conditions or interfere with treatments.

This article is for informational purposes only and does not constitute medical advice. Always consult your dermatologist, physician, or healthcare provider before starting any supplement. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

HathawayMD.com Editorial Team | July 2026

Biotin Interference with Laboratory Tests: Troponin, Thyroid, and Diagnostic Accuracy Warnings

Safety Overview

Biotin (vitamin B7) is marketed as a “hair, skin, and nail” supplement and enjoys widespread popularity among dermatology patients seeking faster hair growth and stronger nails. However, biotin poses an insidious and often-overlooked danger: at high doses (>2.5 mg daily), it interferes with immunoassay-based laboratory tests, producing false results for critical cardiac and endocrine markers. A patient taking 10 mg biotin daily—a common dose in over-the-counter hair/skin products—may receive a falsely reassuring troponin test after chest pain, falsely low TSH in thyroid screening, or falsely elevated vitamin B12. These errors have direct clinical consequences: missed myocardial infarctions, delayed thyroid cancer diagnosis, and inappropriate medication adjustments. This represents a critical safety gap where supplement use creates direct diagnostic harm, not just side effects.

Who Is Most at Risk

Individuals taking high-dose biotin supplements (≥2.5 mg daily), particularly those with concurrent cardiovascular risk factors who might undergo troponin testing. Patients with thyroid disease (hypothyroidism, Graves', thyroid cancer) undergoing TSH or free T4 monitoring—biotin interference could mask thyroid dysfunction or delayed treatment initiation. Older adults with polypharmacy and multiple comorbidities who undergo routine screening labs. People taking “biotin + collagen” or “hair growth” supplement combinations without checking actual biotin content. Dermatology patients using prescription tretinoin or other anti-aging products who are also supplementing with biotin for “synergistic” hair and skin benefits.

Drug Interaction Deep Dive

Troponin Testing (Cardiac Marker) Interference

MODERATE RISK (severity escalates if patient presents with chest pain or suspected acute coronary syndrome) — Biotin interferes with electrochemiluminescence immunoassays (ECLIA), the predominant troponin assay platform in U.S. hospitals. Biotin competes for capture antibodies in the assay, producing artificially LOW troponin values. A patient with acute myocardial infarction taking 5-10 mg biotin daily may receive troponin results in the normal range despite active myocardial necrosis, delaying diagnosis and treatment by hours—the critical window for percutaneous coronary intervention or thrombolytics.

Evidence Level: Well-documented; FDA safety communication (2019); multiple case reports of missed MIs. Monitoring: If biotin is being taken, DISCLOSE it to emergency department or laboratory before troponin testing. Labs should be aware and may retest using alternative platforms or delay biotin supplementation 24-48 hours before testing. Recommendation: Patients with known cardiovascular risk factors or those undergoing cardiac evaluation should AVOID high-dose biotin (>2.5 mg daily). If biotin is essential for dermatologic reasons, limit to ≤1 mg daily, and disclose to any healthcare provider ordering troponin tests.

TSH and Free T4 Testing (Thyroid Function)

MODERATE RISK — Biotin interferes with ECLIA-based TSH and free T4 assays, typically producing FALSE LOW TSH and FALSE HIGH free T4 values. This mimics thyroid overactivity or can mask hypothyroidism. Patients on levothyroxine (Synthroid) replacement may appear to have excessive thyroid hormone, leading physicians to inappropriately reduce doses, resulting in real hypothyroidism and fatigue, weight gain, and cognitive dysfunction. Patients with thyroid cancer undergoing TSH suppression therapy may appear over-suppressed when they're actually at target.

Evidence Level: Well-documented; FDA warning (2017); American Thyroid Association alerts. Monitoring: TSH testing should occur with awareness of biotin use. If possible, withhold biotin for 48 hours before TSH testing, or retest after biotin discontinuation. Recommendation: Patients with thyroid disease or those undergoing thyroid screening should LIMIT biotin to ≤1 mg daily. Disclose biotin use to endocrinologist or primary care provider before any TSH or free T4 testing. Consider avoiding biotin entirely if thyroid function is unstable or undergoing active adjustment.

Vitamin B12 and Folate Serum Level Testing

LOW RISK — Biotin can produce falsely HIGH vitamin B12 values, potentially masking B12 deficiency. However, this is less clinically catastrophic than troponin or TSH interference because clinical symptoms of B12 deficiency (paresthesia, cognitive changes) would eventually prompt evaluation. Still, it can delay diagnosis and allow neurologic complications to progress.

Evidence Level: Documented but less common than troponin/TSH interference. Monitoring: Disclose biotin use when B12 levels are checked. Consider clinical symptoms as primary guide to B12 status. Recommendation: Lower risk but still recommends disclosure to provider. If B12 deficiency is suspected, withhold biotin for 48 hours before testing or retest after discontinuation.

Creatinine and eGFR (Kidney Function) Interference

THEORETICAL — Some ECLIA platforms show creatinine interference with high-dose biotin, though this is less consistently documented than troponin or TSH interference. If present, it would produce artificially LOW creatinine, masking kidney dysfunction. Risk is primarily theoretical at this time, pending further data.

Evidence Level: Mechanistic; limited clinical documentation. Monitoring: None established. Recommendation: Disclose biotin use to provider if kidney function testing is planned.

HCG (Pregnancy Testing) Interference

LOW RISK — Biotin may interfere with HCG immunoassays, potentially producing false results. Risk is theoretically highest with very high biotin doses (>5 mg daily) and certain assay platforms. This is a concern for reproductive-age dermatology patients taking high-dose biotin “hair growth” supplements while trying to conceive or avoid conception.

Evidence Level: Mechanistic; limited clinical documentation. Monitoring: If pregnancy is suspected or confirmation needed, disclose biotin use to provider. Consider urine HCG (less susceptible to biotin interference) or quantitative serum HCG if results are inconclusive. Recommendation: Women of childbearing age should disclose biotin use before pregnancy testing. Limit biotin to ≤2 mg daily if planning pregnancy or breastfeeding to minimize any potential exposure-related risks.

Biotin Dose and Interference Risk

≤1 mg daily: Minimal to no documented assay interference. Generally safe for chronic supplementation.

2.5-5 mg daily: Documented interference with troponin, TSH, free T4. Risk increases with dose. Use cautiously; disclose to healthcare providers.

>10 mg daily: Significant documented interference. AVOID if undergoing cardiac or thyroid testing. HIGH RISK of diagnostic error.

Note: Many over-the-counter “hair, skin, and nails” supplements contain 5-10 mg biotin per dose. Patients often take these unaware of interference risk.

Contraindicated Populations

Patients with Known Cardiovascular Disease or Risk Factors: AVOID high-dose biotin. If supplementing, keep below 1 mg daily. Disclose to all healthcare providers.

Thyroid Disease Patients (Any Form): AVOID high-dose biotin. Limit to ≤1 mg daily if supplementing. Coordinate with endocrinologist.

Patients Scheduled for Cardiac Testing or Troponin Evaluation: AVOID biotin for 48 hours before testing, or disclose to laboratory if stopping is impractical.

Patients Undergoing Thyroid Function Testing: Withhold biotin 48 hours before testing when possible, or disclose to provider/lab.

What to Tell Your Dermatologist and Healthcare Providers

When starting biotin supplementation or updating medications, disclose:

• Exact biotin dose and frequency (many patients underestimate dosing)
• Any product names (e.g., “hair growth supplement” often contains high-dose biotin)
• Cardiovascular risk factors or history
• Thyroid disease or current thyroid medication use
• Planned laboratory testing (cardiac, thyroid, kidney function)
• Pregnancy status or planning

Provide this information BEFORE any laboratory testing is ordered. Give labs advance notice of biotin use so they can plan for potential retesting or alternative assay platforms.

Safer Alternatives for Hair, Skin, and Nail Support

For dermatologic benefits without biotin interference risk: silica supplementation (no documented assay interference), collagen peptides (low risk; some minimal B12 interference but not concerning), niacinamide (no assay interference; direct skin benefits), zinc supplementation (minimal interference risk at normal doses), or iron supplementation (if deficient; no assay interference). These alternatives provide hair and skin support without diagnostic hazard.

This dermatological safety reference is provided for informational and educational purposes only. It does not constitute medical advice, clinical guidance, or a substitute for individualized evaluation by a qualified dermatologist or healthcare provider. Drug interaction severity can vary based on individual factors including dose, skin type, sun exposure, genetic metabolism, and co-existing conditions. Never discontinue or modify a dermatologic medication without your physician's guidance. HathawayMD.com is an independent editorial publication and is not affiliated with any hospital, clinic, dermatology practice, or medical provider.